Preclinical development of the CDK4 selective inhibitor PF-07220060: Increased CDK4 versus CDK6 inhibition leads to improved anti-tumor efficacy at therapeutic concentrations

被引：0
|
作者：
Anders, Lars
Pascual, Bernadette
Boras, Britton
Cianfrogna, Julie
Garza, Scott
Li, Na
Yuan, Jing Tang
Moen, Mark
Huser, Nanni
Gallego, Gary
Jalaie, Mehran
Ninkovic, Sacha
Cho-Schultz, Sujin
Shen, Hong
Kath, John
Dress, Klaus
Diehl, Wade
Nair, Sajiv
Jones, Rhys
Lafontaine, Jennifer
Murtaza, Anwar
Sacaan, Aida
Chintharlapalli, Sudhakar
VanArsdale, Todd
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
595
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Modulation of anti-tumor immunity using CDK4/6 using
    Goel, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
    Sun, Ran
    Wang, Xuemei
    Zhang, Leichao
    Gu, Yu
    Yang, Shaojuan
    Wang, Liping
    Wang, Xueju
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
    Digiacomo, Graziana
    Fumarola, Claudia
    La Monica, Silvia
    Bonelli, Mara
    Cavazzoni, Andrea
    Galetti, Maricla
    Terenziani, Rita
    Eltayeb, Kamal
    Volta, Francesco
    Zoppi, Silvia
    Bertolini, Patrizia
    Missale, Gabriele
    Alfieri, Roberta
    Petronini, Pier Giorgio
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
    Sun, Chao-Yue
    Talukder, Milton
    Cao, Di
    Chen, Cun-Wu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [26] Targeting Non-Kinase Function of CDK6 to Overcome CDK4/6 Inhibitor Resistance
    Alluri, P. G.
    Udden, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S44 - S44
  • [27] Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
    Poulikakos, P.
    Wu, X.
    Yang, X.
    Xiong, Y.
    Ito, T.
    Ahmed, T.
    Karoulia, Z.
    Adamopoulos, C.
    Li, R.
    Wang, H.
    Wang, L.
    Xie, L.
    Liu, J.
    Ueberheide, B.
    Aaronson, S.
    Chen, X.
    Buchanan, S.
    Sellers, W.
    Jin, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S5 - S5
  • [28] Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
    Xuewei Wu
    Xiaobao Yang
    Yan Xiong
    Ruitong Li
    Takahiro Ito
    Tamer A. Ahmed
    Zoi Karoulia
    Christos Adamopoulos
    Hong Wang
    Li Wang
    Ling Xie
    Jing Liu
    Beatrix Ueberheide
    Stuart A. Aaronson
    Xian Chen
    Sean G. Buchanan
    William R. Sellers
    Jian Jin
    Poulikos I. Poulikakos
    Nature Cancer, 2021, 2 : 429 - 443
  • [29] Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
    Wu, Xuewei
    Yang, Xiaobao
    Xiong, Yan
    Li, Ruitong
    Ito, Takahiro
    Ahmed, Tamer A.
    Karoulia, Zoi
    Adamopoulos, Christos
    Wang, Hong
    Wang, Li
    Xie, Ling
    Liu, Jing
    Ueberheide, Beatrix
    Aaronson, Stuart A.
    Chen, Xian
    Buchanan, Sean G.
    Sellers, William R.
    Jin, Jian
    Poulikakos, Poulikos I.
    NATURE CANCER, 2021, 2 (04) : 429 - +
  • [30] Preclinical development of a highly potent and selective dual inhibitor of CDK4/6 for the treatment of cancer
    Bantie, Laychiluh
    Tadesse, Solomon
    Likisa, Jimma
    Yu, Mingfeng
    Noll, Benjamin
    Albrecht, Hugo
    Milne, Robert
    Wang, Shudong
    CANCER RESEARCH, 2018, 78 (13)
12345